<DOC>
	<DOC>NCT02537691</DOC>
	<brief_summary>Prospective, single-arm, longitudinal, international, multicenter study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.</brief_summary>
	<brief_title>Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Asthma diagnosed by a respiratory physician greater than or equal to (&gt;/=) 12 months prior to study enrolment Prebronchodilator FEV1 of 30 percent (%) to 85% at baseline/Visit 1 Documented bronchodilator response defined as &gt;/=12% relative improvement in FEV1 after bronchodilator administration or a positive methacholine bronchial challenge test with provocative concentration causing a 20% fall in FEV1 (PC20) less than (&lt;) 8 milligrams (mg) at study baseline/Visit 1 or within 24 months prior to baseline Current treatment with a total daily dose of &gt;/= 500 micrograms (mcg) of fluticasone propionate (FP) dry powder inhaler (DPI) (or equivalent ) and at least one of the following controller medications: longacting Betaagonist (LABA), leukotriene receptor antagonist (LTRA), longacting muscarinic antagonists (LAMAs), theophylline or oral corticosteroids, with a continued duration of three months prior to baseline/Visit 1 Acute or chronic parasitic, bacterial, fungal or viral infections that required, or currently require, hospitalization or antimicrobial treatment during the last four weeks prior to participant eligibility Acute asthma exacerbation event treated with increased doses of oral, or any dose of intramuscular (IM) or intravenous (IV) corticosteroids within six weeks prior to study Other relevant pulmonary diseases (e.g. chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to baseline/Visit 1 Exsmokers with &gt;/=10 packyear smoking history Prior treatment with bronchial thermoplasty Participation in any clinical trial of an investigational agent or procedure within six months prior to baseline/Visit 1 or during the study Pregnancy prior to participation or during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>